Cedirogant

DRUG2 trials

Sponsors

AbbVie

Conditions

Hepatic ImpairmentPsoriasis

Phase 1

A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

TerminatedNCT05376839

AbbVieHepatic Impairment

Start: 2022-07-06End: 2022-11-08Updated: 2022-12-08

Phase 2

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

TerminatedNCT05044234

AbbViePsoriasis

Start: 2021-11-16End: 2022-11-30Updated: 2023-11-29

Related Papers

Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial

Clinical and Experimental Dermatology2024-05-039 citations